noom and glp-1 Rebel Wilson Touts Micro Habits, Microdosed GLP-1s For 09/22/2025 Noom's GLP-1 Companion Receives Major

Haas JD, Gonzlez FH, Schmitz S, Chennupati V, Fhse L, Kremmer E, et al

Will it produce dramatic, prescription-level results

Because so many people are taking these medications, insurance companies end up paying a lot for all the prescriptions

It does maintain a Willow Facebook Community for patients to connect with each other

While Ozempic has data to support its cardiovascular risk reduction, Rybelsus does not, she says

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape